SG148197A1 - Method for proliferating cardiomyocytes - Google Patents

Method for proliferating cardiomyocytes

Info

Publication number
SG148197A1
SG148197A1 SG200808669-6A SG2008086696A SG148197A1 SG 148197 A1 SG148197 A1 SG 148197A1 SG 2008086696 A SG2008086696 A SG 2008086696A SG 148197 A1 SG148197 A1 SG 148197A1
Authority
SG
Singapore
Prior art keywords
cip
kip family
cardiomyocytes
family protein
production
Prior art date
Application number
SG200808669-6A
Other languages
English (en)
Inventor
Mimi Adachi
Keiichi Nakayama
Shigetaka Kitajima
Hiromitsu Takagi
Original Assignee
Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asubio Pharma Co Ltd filed Critical Asubio Pharma Co Ltd
Publication of SG148197A1 publication Critical patent/SG148197A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
SG200808669-6A 2003-11-21 2004-11-19 Method for proliferating cardiomyocytes SG148197A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003391708 2003-11-21
JP2004246533 2004-08-26

Publications (1)

Publication Number Publication Date
SG148197A1 true SG148197A1 (en) 2008-12-31

Family

ID=34622192

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200808669-6A SG148197A1 (en) 2003-11-21 2004-11-19 Method for proliferating cardiomyocytes

Country Status (15)

Country Link
US (1) US20070009496A1 (ru)
EP (1) EP1693451B1 (ru)
JP (1) JP4809061B2 (ru)
KR (1) KR101169980B1 (ru)
CN (1) CN1882687B (ru)
AT (1) ATE532863T1 (ru)
AU (1) AU2004291809B2 (ru)
BR (1) BRPI0416732A (ru)
CA (1) CA2545049A1 (ru)
DK (1) DK1693451T3 (ru)
ES (1) ES2376239T3 (ru)
IL (1) IL175264A0 (ru)
RU (1) RU2378375C2 (ru)
SG (1) SG148197A1 (ru)
WO (1) WO2005049822A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090285791A1 (en) * 2008-05-15 2009-11-19 Sbarro Health Research Organization, Inc. Regenerating and enhancing development of muscle tissue
BR112012022946A2 (pt) * 2010-03-12 2017-02-07 Daiichi Sankyo Co Ltd método para proliferar cardiomiócitos usando micro-rna
JP6090855B2 (ja) 2010-11-17 2017-03-08 国立大学法人京都大学 心筋細胞および／または心筋前駆細胞増殖剤ならびに心筋細胞および／または心筋前駆細胞の増殖方法
RU2466391C1 (ru) * 2011-03-28 2012-11-10 Государственное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России) Способ диагностики рецидивирующей кровопотери
US9868937B2 (en) 2011-05-26 2018-01-16 University Of Washington Cell and gene based methods to improve cardiac function
CN102382127A (zh) * 2011-09-23 2012-03-21 复旦大学 特异性促进心肌细胞发生增殖的心肌小分子化合物及其应用
JPWO2014038655A1 (ja) * 2012-09-07 2016-08-12 国立大学法人京都大学 腸上皮由来体性幹細胞の製造方法
EP3259346A4 (en) * 2015-02-20 2018-07-11 Baylor College of Medicine P63 inactivation for the treatment of heart failure
JP6960396B2 (ja) * 2015-04-07 2021-11-05 ザ ジェイ． デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デビッド グラッドストーン 分裂終了細胞の細胞分裂を誘発するための方法
CN110907644B (zh) * 2019-12-11 2023-01-06 深圳市达科为生物工程有限公司 多种细胞鉴定试剂盒及操作方法
CN113061573B (zh) * 2021-05-21 2023-03-24 苏州大学 间歇性饥饿促进心肌细胞成熟的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1126866B1 (en) * 1998-11-02 2007-02-07 The Regents of The University of California A mutant phospholamban molecule and its use in the treatment of cardiac disease and heart failure
US7795032B2 (en) * 2001-05-17 2010-09-14 Masaaki Ikeda Methods for proliferating cardiomyocytes and recombinant vectors therefor
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization

Also Published As

Publication number Publication date
EP1693451A4 (en) 2007-11-07
EP1693451A1 (en) 2006-08-23
EP1693451B1 (en) 2011-11-09
ATE532863T1 (de) 2011-11-15
JP4809061B2 (ja) 2011-11-02
BRPI0416732A (pt) 2007-01-16
ES2376239T3 (es) 2012-03-12
CN1882687A (zh) 2006-12-20
RU2006121980A (ru) 2007-12-27
CA2545049A1 (en) 2005-06-02
JPWO2005049822A1 (ja) 2007-06-07
KR101169980B1 (ko) 2012-07-31
RU2378375C2 (ru) 2010-01-10
IL175264A0 (en) 2006-09-05
WO2005049822A1 (ja) 2005-06-02
AU2004291809A1 (en) 2005-06-02
US20070009496A1 (en) 2007-01-11
KR20060125760A (ko) 2006-12-06
CN1882687B (zh) 2012-07-04
AU2004291809B2 (en) 2010-05-20
DK1693451T3 (da) 2012-02-13

Similar Documents

Publication Publication Date Title
IL175264A0 (en) Method for proliferating cardiomyocytes
WO2006119987A3 (en) Recombinant n-glycosylated proteins from procaryotic cells
WO2005072129A9 (en) Production of host cells containing mutiple integrating vectors by serial transduction
WO2002066622A3 (en) Method of generating diversity into lipolytic enzymes and lipolytic enzyme genes
WO2005121332A3 (en) Truncated st6galnaci polypeptides and nucleic acids
WO2000075350A3 (en) Nucleic acid sequences encoding proteins involved in fatty acid beta-oxidation and methods of use
ATE309536T1 (de) Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
DE502004005166D1 (de) Expressionsvektor zur antibiotikafreien expression
MXPA05013526A (es) Secuencias de acido nucleico que codifican y composiciones que comprenden el peptido de senal de ige y/o il-15 y metodos para uso de los mismos.
MXPA05005202A (es) Vacuna.
DE602004031642D1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
WO2002048329A3 (en) Membrane derived caspase-3, compositions comprising the same and methods of use therefor
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
WO2000044906A3 (en) GENES IDENTIFIED AS REQUIRED FOR PROLIFERATION IN $i(ESCHERICHIA COLI)
FI961202A0 (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
EP1412374A4 (en) NEW PGC-1 ISOFORMS AND THEIR USES
Müller et al. The chemokine networks in sponges: potential roles in morphogenesis, immunity and stem cell formation
WO2005007803A3 (en) Selection free growth of host cells containing multiple integrating vectors
AU2001280639A1 (en) 13237,18480,2245 or 16228 human protein kinase molecules and uses therefor
WO2003025153A3 (en) Enhanced proteins and methods for their use
DE69031996D1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
WO2002028893A3 (en) Plant cyclin-dependent kinase inhibitors